Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.

Tural, DenizArslan, ÇağataySelçukbiricik, FatihÖlmez, Ömer FatihAkar, EmreErman, MustafaÜrün, YükselErdem, DilekKılıçkap, Saadettin2023-12-112023-12-112023Tural, D., Arslan, Ç., Selçukbiricik, F., Ölmez, Ö. F., Akar, E., Erman, M. ... Kılıçkap, S. (2023). Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma. Genitourinary Cancers Symposium. Electrical Network, 16-18 February, 2023.0732-183X1527-7755https://hdl.handle.net/20.500.12511/11977[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessMetastatic Urothelial CarcinomaCheckpoint InhibitorsLong-Term Overall SurvivalObjective ResponseComparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.Conference Object41Supplement: 6Q1001098050200510